Pascua Irene, Fernández-Marcelo Tamara, Sánchez-Pernaute Andrés, de Juan Carmen, Head Jacqueline, Torres-García Antonio-José, Iniesta Pilar
aDepartment of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University bSurgery Service, San Carlos Hospital, Institute for Health Research from San Carlos Hospital (IdISSC), Madrid, Spain.
Eur J Gastroenterol Hepatol. 2015 Feb;27(2):162-9. doi: 10.1097/MEG.0000000000000250.
To identify molecular markers that may be useful in the selection of gastric cancer patients with different prognoses, we investigated telomere function in gastric cancers with and without microsatellite instability (MSI).
We analyzed 83 gastric cancers and its paired-normal tissues to investigate MSI and telomere function. MSI was established using five polymorphic human repeat DNA markers. Telomere function was evaluated by determining telomerase activity, telomere length, and telomere-repeat factors 1 and 2 (TRF1 and TRF2) expression.
Patients with high microsatellite instability (MSI-H) gastric cancers showed a significantly better prognosis than those affected by microsatellite stable or low microsatellite instability (MSS/MSI-L) tumors (P = 0.03). The lowest expression levels of TRF1 and TRF2 were associated with MSI-H gastric cancers (P = 0.008 and 0.006, respectively). Moreover, a clear trend toward a worse prognosis was found in the group of patients who had tumors with the shortest telomeres (P = 0.01). Cox multivariate analysis showed that MSI emerged as a protective prognostic factor; MSS/MSI-L tumors conferred a significantly poor prognosis in patients (relative risk = 4.862-fold greater than the MSI-H group) (P = 0.033). Telomere length of gastric tumors less than 2.86 kbp was a factor that led to a poor prognosis (relative risk = 4.420, with respect to tumors showing telomere length ≥ 2.86 kbp) (P = 0.002).
We propose telomere status as a potential molecular marker with usefulness in the establishment of the prognosis of gastric cancers both for the mutator phenotype and for the suppressor pathway.
为了鉴定可能有助于筛选不同预后胃癌患者的分子标志物,我们研究了伴有和不伴有微卫星不稳定性(MSI)的胃癌中的端粒功能。
我们分析了83例胃癌及其配对的正常组织,以研究MSI和端粒功能。使用5种多态性人类重复DNA标记确定MSI。通过测定端粒酶活性、端粒长度以及端粒重复因子1和2(TRF1和TRF2)的表达来评估端粒功能。
微卫星高度不稳定(MSI-H)胃癌患者的预后明显好于微卫星稳定或微卫星低度不稳定(MSS/MSI-L)肿瘤患者(P = 0.03)。TRF1和TRF2的最低表达水平与MSI-H胃癌相关(分别为P = 0.008和0.006)。此外,在端粒最短的肿瘤患者组中发现了预后较差的明显趋势(P = 0.01)。Cox多变量分析显示,MSI是一种保护性预后因素;MSS/MSI-L肿瘤患者的预后明显较差(相对风险比MSI-H组高4.862倍)(P = 0.033)。胃肿瘤端粒长度小于2.86 kbp是导致预后不良的一个因素(相对于端粒长度≥2.86 kbp的肿瘤,相对风险 = 4.420)(P = 0.002)。
我们提出端粒状态作为一种潜在的分子标志物,对于通过突变体表型和抑制途径确定胃癌的预后具有实用性。